Results 111 to 120 of about 78,382 (206)

BRAF Inhibitor Resistance in Melanoma: Mechanisms and Alternative Therapeutic Strategies. [PDF]

Curr Treat Options Oncol, 2022
Zhong J, Yan W, Wang C, Liu W, Lin X, Zou Z, Sun W, Chen Y.   +7 more
europepmc   +1 more source

BRAF Inhibitors and Control of Mutant BRAF Effects

Cancer Therapy & Oncology International Journal, 2023
openaire   +1 more source

Integrative CRISPR Activation and Small Molecule Inhibitor Screening for lncRNA Mediating BRAF Inhibitor Resistance in Melanoma. [PDF]

Biomedicines, 2023
Shamloo S, Kloetgen A, Petroulia S, Hockemeyer K, Sievers S, Tsirigos A, Aifantis I, Imig J.   +7 more
europepmc   +1 more source

The risk of radiation necrosis from combined radiotherapy and BRAF inhibitor in lung adenocarcinoma brain metastases: a comprehensive review and future perspectives. [PDF]

Front Oncol
Yang L, He Y, Peng Y, Sun M, Tang Z, Du L, Wu Y, Zhou W, Yang D.   +8 more
europepmc   +1 more source

Rapid symptomatic improvement in two patients with ganglioglioma after restarting BRAF inhibitor therapy. [PDF]

Pediatr Blood Cancer, 2023
Cantor E, Berkovich R, Navalkele P, Brossier NM.   +3 more
europepmc   +1 more source

BRAF inhibitor-induced necrotizing granulomatous lymphadenopathy: a case report of drug-induced sarcoid-like reaction. [PDF]

Proc (Bayl Univ Med Cent)
Firouzbakht S, Rizvi A, Mosher A, Yaqub S, Sigler M.   +4 more
europepmc   +1 more source

Fibronectin Contributes to a BRAF Inhibitor-driven Invasive Phenotype in Thyroid Cancer through EGR1, Which Can Be Blocked by Inhibition of ERK1/2. [PDF]

Mol Cancer Res, 2023
Hicks HM, Pozdeyev N, Sams SB, Pugazhenthi U, Bales ES, Hofmann MC, McKenna LR, Schweppe RE.   +7 more
europepmc   +1 more source

Long term response on Regorafenib in non-V600E BRAF mutated colon cancer: a case report [PDF]

, 2019
Callebout, Eduard, Claes, Kathleen, De Man, Marc, Ferdinande, Liesbeth, Geboes, Karen, Laurent, Stéphanie, Moura Ribeiro, Suzane, Van der Meulen, Joni   +7 more
core   +2 more sources

Sustained Response to Pan-BRAF Inhibitor Plixorafenib (FORE8394, PLX8394) in a Young Adult With Neurodegenerative Langerhans Cell Histiocytosis. [PDF]

JCO Precis Oncol
Yi JS, McCarthy KS, Mazur K, Kudlaty R, Armstrong T, Desai N, Shepherd SP, Zinn D, Velazquez J, Scull B, Allen C, McClain K.   +11 more
europepmc   +1 more source

MUC1-C is necessary for SHP2 activation and BRAF inhibitor resistance in BRAF(V600E) mutant colorectal cancer. [PDF]

Cancer Lett, 2023
Morimoto Y, Yamashita N, Hirose H, Fushimi A, Haratake N, Daimon T, Bhattacharya A, Ahmad R, Suzuki Y, Takahashi H, Kufe DW.   +10 more
europepmc   +1 more source